Alternative Investment Funds
United States
12 September 2024
Leveraging cross-border capabilities with Caribbean and Middle Eastern jurisdictions, Dechert LLP boasts a strong track record in private placements, IPOs, and public offerings of common stock. Advising both issuers and underwriters, the team is highly knowledgeable on equity-linked and other securities offerings, with Boston-based Thomas Friedmann routinely navigating sensitive disclosure matters under the Securities Exchange Act of 1934. From Washington DC, Harry Pangas concentrates on joint ventures and other strategic transactions, in New York, David Rosenthal acts for investment banks and venture capital funds, while Philadelphia’s Stephen Leitzell stands out for his corporate governance work.
Legal 500 Editorial commentary
Key clients
- Aquestive Therapeutics
- B&G Foods
- Bain Capital Specialty Finance
- BC Partners
- BioAtla
- Blackstone
- Business Development Company of America
- Diffusion Therapeutics
- EaglePoint Credit Company
- FS Investment Corporation
Work highlights
Advising Select Medical Holdings Corporation and Concentra Group Holdings Parent, Inc., a subsidiary of Select Medical, in connection with the contemplated spin-off of Concentra from SelectMedical.
Represented AB Private Credit Investors LLC in connection with the formation and launch ofAB Private Lending Fund, a publicly offered non-traded business development company.
Represented Morgan Stanley Direct Lending Fund (the “Company”) (NYSE: MSDL), a business development company externally managed by MS Capital Partners Adviser Inc., in its initial public offering of 5,000,000 shares of its common stock, par value $0.001 per share (the “Common Stock”), at a public offering price of $20.67 per share of Common Stock.
Lawyers
Practice head
Thomas Friedmann; Stephen Leitzell; Harry Pangas; Anna Tomczyk
Other key lawyers
David Rosenthal; Eric Siegel; Clay Douglas; Matthew Carter